USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/12763
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDoroschevici, Alina
dc.contributor.authorSafta, Vladimir
dc.date.accessioned2020-11-10T06:41:51Z
dc.date.available2020-11-10T06:41:51Z
dc.date.issued2020-10
dc.identifier.urihttp://repository.usmf.md/handle/20.500.12710/12763
dc.identifier.urihttps://stiinta.usmf.md/ro/manifestari-stiintifice/zilele-universitatii
dc.descriptionDepartment of Social Pharmacy “Vasile Procopisin”, Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină și Farmacie „Nicolae Testemițanu” din Republica Moldova, Ziua internațională a științei pentru pace și dezvoltareen_US
dc.description.abstractPurpose: Research of legislation and highlight the peculiarities of pharmaceutical control in the countries of the EU, CIS,. Southeast Asia. Results: Pharmaceutical control. The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU medicines. To fulfill its mission, the European Medicines Agency (EMA) works closely with national competent authorities in a regulatory network. The Agency also implements policies and procedures to ensure it works independently, openly and transparently and support the highest standards in its scientific recommendations. In the Commonwealth of Independent States (CIS) countries the pharmaceutical control function is a component part of the Ministries of Health, or there are special departments. The Council of the Eurasian Economic Commission (RUS, BLR, KAZ, ARM, KGZ) approved a single decision to conduct pharmaceutical inspections. Thus the inspection is carried out by a pharmaceutical inspectorate on the basis of an inspection plan, an inspection request or at the request of an authorized body of a Member State. All countries in the Southeast Asia (SEA) region have a shortage of drug insurance for the population. Although progress has been made, challenges remain in delivering the right drugs at the right time. National regulatory agencies (NRAs) protect public health by ensuring the efficacy, safety and quality of medicines, but with the development of the pharmaceutical market, financial and human resources are often limited. Thus, some NRAs may legitimately decide to rely on other competent regulatory authorities to fulfill Pharmaceutical control has a common goal regardless of the country, namely ensuring the quality of the drug at all stages: production, distribution, up to marketing in pharmacies and use by the patient. National medicines policies and laws are the basis for good governance and coordination in the pharmaceutical sector. An effective national drug policy establishes the state's commitment to ensuring equitable access to effective, safe and quality medicines.en_US
dc.language.isoenen_US
dc.publisherUniversitatea de Stat de Medicină şi Farmacie "Nicolae Testemiţanu"en_US
dc.subjectpharmaceutical controlen_US
dc.titlePharmaceutical control in EU countries, CIS, Southeast Asiaen_US
dc.typeOtheren_US
Appears in Collections:Culegere de postere

Files in This Item:
File Description SizeFormat 
Pharmaceutical_control_in_EU_countries_CIS_Southeast_Asia.pdf1.3 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback